Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer

Oncology Reports

Volumn 14, Issue 2, 2005, Pages 433-439

  Hotta, Tsukasa ^a   Takifuji, Katsunari ^a   Arii, Kazuo ^a   Yokoyama, Shozo ^a   Matsuda, Kenji ^a   Higashiguchi, Takashi ^a   Tominaga, Toshiji ^a   Oku, Yoshimasa ^a   Yamaue, Hiroki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Colorectal cancer; l LV 5FU; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; FLUOROURACIL; FOLINIC ACID;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLOOD; BONE MARROW; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; THROMBOCYTE COUNT; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BLOOD GLUCOSE; BONE MARROW; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CREATININE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATELET COUNT; TIME FACTORS; TREATMENT OUTCOME;

EID: 24744465896     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.2.433     Document Type: Article

References (17)

1. Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, Marsili S, Aquino A, Marzocca G, Civitelli S, Mariani L, de Sando D, Bovenga S and Lorenzi M: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterol 106: 899-906, 1994. (Pubitemid 24109275)
2. Hotta T, Taniguchi K, Kobayashi Y, Johata K, Sahara M, Naka T, Watanabe T, Ochiai M, Tanimura H and Tsubota YT: Comparative analysis of thymidine Phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and colorectal cancers. Oncol Rep 11: 1045-1051, 2004.
3. Evans RM, Laskin JD and Hakala MT: Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3288-3295, 1981. (Pubitemid 11063590)
4. Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwald ES, Bukowski RM, Harris J, Levin B, Gaynor E, Loutfi A, Kaiser MH, Barkin JS, Benedetto P, Woolley PV, Nauta R, Weaver DW and Leichman LP: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7: 1419-1426, 1989. (Pubitemid 19245111)
5. Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, Emrich LJ and Mittelman A: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559-1565, 1987. (Pubitemid 18010132)
6. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, Spurr CL, Dimitrov N, Romond EH, Sutherland CM, Kardinal CG, deFusco PA and Jochimsen P: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11: 1879-1887, 1993. (Pubitemid 23304611)
7. Zhang ZG and Rustum YM: Pharmacologic rationale for fluoropyrimidine- leucovorin combination: biochemical mechanisms. Semin Oncol 19: 46-50, 1992.
8. Scheithauer W, Kornek G, Marczeil A, Salem G, Karner J, Kovats E, Burger D, Greiner R, Pidlich J, Schneeweiss B, Raderer M, Rosen H and Depisch D: Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. J Clin Oncol 15: 908-914, 1997. (Pubitemid 27106271)
9. Goldberg RM, Hatfield AK, Kahn M, Sargent DJ, Knost JA, O'Connell MJ, Krook JE, Mailliard JA, Wiesenfeld M, Schaefer PL, Tirona MT and Moertel CG: Prospectively randomized North Central Cancer Treatment Group Trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 15: 3320-3329, 1997. (Pubitemid 27485850)
10. Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG and Mailliard JA: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967-1972, 1991.
11. Cutsem EV, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C and Harper P: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106, 2001. (Pubitemid 33049527)
12. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO and Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282-2292, 2001. (Pubitemid 32366981)
13. De Gramont A, Bosset JF, Milan C, Rougier P, Boushé O, Etienne PL, Morvan F, Louvet C, Guillot T, François E and Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808-815, 1997. (Pubitemid 27074252)
14. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000. (Pubitemid 30644117)
15. UICC: TNM classification of malignant tumors. 4th edition. Berlin Heidelberg, Springer-Verlag, New York, 1997.
16. Konishi K, Yabushita K, Taguchi T, Ota J, Takashima S, Abe T, Kikkawa N, Yasutomi M, Sowa M, Maehara Y, Arima S, Isomoto H, Kurihara M, Ohtani T, Hirabayashi N and Nakano S: A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. Jpn J Cancer Chemother 22: 925-932, 1995.
17. Yoshino M, Ota K, Kurihara M, Akazawa S, Tominaga T, Sasaki T, Konishi T, Kodaira S, Kumai K, Sugano K, Ogawa M, Ariyoshi Y and Murakami M: Late phase II trial of high-dose l-leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Jpn J Cancer Chemother 22: 785-792, 1995.